These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 25274033)
1. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033 [TBL] [Abstract][Full Text] [Related]
2. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371 [TBL] [Abstract][Full Text] [Related]
3. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305 [TBL] [Abstract][Full Text] [Related]
4. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. An J; Wang C; Deng Y; Yu L; Huang H Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459 [TBL] [Abstract][Full Text] [Related]
5. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression. Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355 [TBL] [Abstract][Full Text] [Related]
6. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Blattner M; Liu D; Robinson BD; Huang D; Poliakov A; Gao D; Nataraj S; Deonarine LD; Augello MA; Sailer V; Ponnala L; Ittmann M; Chinnaiyan AM; Sboner A; Chen Y; Rubin MA; Barbieri CE Cancer Cell; 2017 Mar; 31(3):436-451. PubMed ID: 28292441 [TBL] [Abstract][Full Text] [Related]
8. Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study. Bidot S; Yin J; Zhou P; Zhang L; Deeb KK; Smith G; Hill CE; Xiu J; Bilen MA; Case KB; Tinsley M; Carthon B; Harik LR Arch Pathol Lab Med; 2024 Mar; 148(3):310-317. PubMed ID: 37327205 [TBL] [Abstract][Full Text] [Related]
9. Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants. Zhang P; Gao K; Tang Y; Jin X; An J; Yu H; Wang H; Zhang Y; Wang D; Huang H; Yu L; Wang C Hum Mutat; 2014 Sep; 35(9):1142-51. PubMed ID: 24990631 [TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591 [TBL] [Abstract][Full Text] [Related]
11. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470 [TBL] [Abstract][Full Text] [Related]
12. Expression and function of androgen receptor coactivators in prostate cancer. Culig Z; Comuzzi B; Steiner H; Bartsch G; Hobisch A J Steroid Biochem Mol Biol; 2004 Nov; 92(4):265-71. PubMed ID: 15663989 [TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells. Zhang L; Peng S; Dai X; Gan W; Nie X; Wei W; Hu G; Guo J Cancer Lett; 2017 Apr; 390():11-20. PubMed ID: 28089830 [TBL] [Abstract][Full Text] [Related]
14. The diverse roles of SPOP in prostate cancer and kidney cancer. Wang Z; Song Y; Ye M; Dai X; Zhu X; Wei W Nat Rev Urol; 2020 Jun; 17(6):339-350. PubMed ID: 32355326 [TBL] [Abstract][Full Text] [Related]
15. Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer. Nikhil K; Haymour HS; Kamra M; Shah K Br J Cancer; 2021 Mar; 124(5):995-1008. PubMed ID: 33311589 [TBL] [Abstract][Full Text] [Related]
16. TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth. Daniels G; Li Y; Gellert LL; Zhou A; Melamed J; Wu X; Zhang X; Zhang D; Meruelo D; Logan SK; Basch R; Lee P Endocr Relat Cancer; 2014 Feb; 21(1):127-42. PubMed ID: 24243687 [TBL] [Abstract][Full Text] [Related]
17. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage. Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763 [TBL] [Abstract][Full Text] [Related]
18. SPOP-mutant prostate cancer: Translating fundamental biology into patient care. Bernasocchi T; Theurillat JP Cancer Lett; 2022 Mar; 529():11-18. PubMed ID: 34974131 [TBL] [Abstract][Full Text] [Related]
19. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Li C; Ao J; Fu J; Lee DF; Xu J; Lonard D; O'Malley BW Oncogene; 2011 Oct; 30(42):4350-64. PubMed ID: 21577200 [TBL] [Abstract][Full Text] [Related]
20. SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. Ma J; Chang K; Peng J; Shi Q; Gan H; Gao K; Feng K; Xu F; Zhang H; Dai B; Zhu Y; Shi G; Shen Y; Zhu Y; Qin X; Li Y; Zhang P; Ye D; Wang C J Exp Clin Cancer Res; 2018 Jul; 37(1):145. PubMed ID: 29996942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]